Trial Profile

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zoldonrasib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions
Sponsors REVOLUTION Medicines

Most Recent Events

03 Jun 2026 Planned primary completion date changed from 30 Apr 2026 to 31 Dec 2026.
06 May 2026 According to a Revolution Medicines media release, data from this study were presented at the American Association for Cancer Research (AACR) Annual Meeting.
19 Apr 2026 Results presented in a Revolution Medicines Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com